RxAll Inc. operates in the pharmaceutical industry, focusing on drug anticounterfeiting and quality assurance. The company serves a diverse clientele including FDAs, hospitals, pharmacies, and big pharmaceutical companies. RxAll's core product is the RxScanner II, an IoT-enabled device that uses deep learning and hyperspectral imaging to authenticate drugs in real time. This technology allows users to identify the quality of prescription drugs, including tablets, powders, and liquids, within 20 seconds without destroying the sample. The RxScanner II is used for rapid quality screening at ports, during post-marketing surveillance, and for confirming the quality of new drug batches delivered by suppliers. RxAll's business model revolves around selling these devices and providing a subscription-based service for real-time global drug quality aggregation data. The company generates revenue through device sales, subscription fees, and partnerships with regulatory bodies and pharmaceutical companies. Supported by leading investors, academics, and donors, RxAll aims to expand its solution to every FDA, hospital, and pharmacy worldwide.

Keywords: drug authentication, IoT, deep learning, hyperspectral imaging, pharmaceutical quality, RxScanner II, FDAs, hospitals, pharmacies, anticounterfeiting.